The Latest Breaking News from Novo Nordisk

Novo CEO ousted in May, in place until successor named

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

While Copenhagen’s fortunes grow alongside rise in Swedish commuters over 16km bridge, benefits for Malmö are proving less obvious

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke to the country’s health secretary to find out more.

Hims Hers Health Inc. (NYSE:HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know.

Has the spectre of Lance Armstrong's doping evaporated or will it come back to haunt the new squad?

Telehealth darling Hims Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable.

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ceasefire in the Israel-Iran conflict